文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Blinatumomab 对比化疗对高危首次复发 B-ALL 儿童无事件生存的影响:随机临床试验

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项随机 3 期试验纳入 108 例高危首次复发 B 细胞急性淋巴细胞白血病儿童,在异基因造血干细胞移植前第三个巩固疗程分别接受 blinatumomab 或化疗。中位随访 22.4 个月时,blinatumomab 组事件发生率为 31%,化疗组为 57%,无事件生存显著改善,且微小残留病缓解率更高、严重不良事件更少。

要点

  • 第三个巩固疗程使用 blinatumomab 较化疗显著改善高危首次复发 B-ALL 儿童的无事件生存。
  • blinatumomab 组微小残留病缓解率为 90%,高于化疗组的 54%。
  • blinatumomab 组严重不良事件和≥3 级不良事件发生率均低于化疗组。

核心结论

  • 在高危首次复发 B-ALL 儿童中,移植前接受 1 个疗程 blinatumomab 较标准强化多药化疗改善无事件生存。
  • 中位随访 22.4 个月时,blinatumomab 组事件发生率为 31%,化疗组为 57%。

研究设计与样本

  • 13 个国家 47 个中心纳入 108 例年龄大于 28 天且小于 18 岁的高危首次复发 B-ALL 儿童,随机分配至 blinatumomab 组(n=54)或化疗组(n=54)。
  • 入组患者随机化时处于形态学完全缓解(M1 骨髓,原始细胞<5%)或 M2 骨髓(原始细胞≥5%且<25%)。
  • blinatumomab 方案为 15 μg/m2/d 连续静脉输注 4 周,用于第三个巩固疗程。
  • 主要终点为无事件生存(事件包括复发、死亡、第二恶性肿瘤或未达到完全缓解),关键次要疗效终点为总生存。

主要发现

  • blinatumomab 组与化疗组事件发生率分别为 31% vs 57%(log-rank P < .001;HR 0.33 [95% CI, 0.18-0.61])。
  • blinatumomab 组死亡 8 例(14.8%),化疗组死亡 16 例(29.6%);总生存 HR 为 0.43(95% CI, 0.18-1.01)。
  • 微小残留病缓解在 blinatumomab 组为 90%(44/49),化疗组为 54%(26/48),差异 35.6%(95% CI, 15.6%-52.5%)。
  • blinatumomab 组与化疗组严重不良事件发生率分别为 24.1% vs 43.1%,≥3 级不良事件发生率分别为 57.4% vs 82.4%。
  • 未报告致死性不良事件;blinatumomab 组有 2 例因不良事件终止治疗。

关键数值与推荐

  • 主要终点无事件生存:blinatumomab 组事件发生率 31%,化疗组 57%,HR 0.33(95% CI, 0.18-0.61),log-rank P < .001。
  • 总生存:HR 0.43(95% CI, 0.18-1.01)。
  • 微小残留病缓解率:blinatumomab 组 90%(44/49),化疗组 54%(26/48),差异 35.6%(95% CI, 15.6%-52.5%)。
  • 严重不良事件发生率:blinatumomab 组 24.1%,化疗组 43.1%;≥3 级不良事件发生率:57.4% vs 82.4%。

临床怎么用

  • 对于高危首次复发 B-ALL 儿童,在异基因造血干细胞移植前第三个巩固疗程可考虑使用 blinatumomab 替代强化化疗。
  • blinatumomab 方案为 15 μg/m2/d 连续静脉输注 4 周,需关注不良事件导致的治疗终止。

局限性

  • 研究因 blinatumomab 获益按预设停止规则提前终止入组。
  • 总生存 HR 的 95% CI 上限为 1.01,跨过无效线。
  • 中位随访时间为 22.4 个月(IQR, 8.1-34.2),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). OBJECTIVE: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant. DESIGN, SETTING, AND PARTICIPANTS: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization. INTERVENTION: Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events. RESULTS: A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group. CONCLUSIONS AND RELEVANCE: Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02393859.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021. PMID: 33651091. doi:10.1001/jama.2021.0987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。